FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.
Retina
; 36(11): 2124-2131, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27333235
ABSTRACT
PURPOSE:
To investigate the efficacy and safety of fluocinolone acetonide intravitreal implant in patients with Vogt-Koyanagi-Harada disease.METHODS:
A post hoc, subgroup analysis on patients with Vogt-Koyanagi-Harada was performed using data sets from two multicenter randomized trials on fluocinolone acetonide implant. Each subject received fluocinolone acetonide implantation in one eye and standard-of-care treatment in the fellow eye and was followed for 3 years.RESULTS:
Thirty patients were included with the mean age of 38.5 years. The cumulative rate of uveitis recurrence for 3 years was significantly reduced in implanted eyes compared with fellow eyes (33 vs. 87%; P < 0.001). The reduction of daily corticosteroid dose was well maintained (12.8 mg before implantation vs. 3.7 mg after implantation; P = 0.001), but final vision was similar to preoperative vision in the implanted eyes (P = 0.082) and in the fellow eyes (P = 0.187). Postoperative elevation of intraocular pressure was more frequent in the implanted eyes than in the fellow eyes (70 vs. 20%; P < 0.001). Cataract progression occurred in all phakic implanted eyes.CONCLUSION:
Fluocinolone acetonide intravitreal implant reduced uveitis recurrence rate and the dosage of systemic corticosteroid and immunosuppressant requirement in patients with Vogt-Koyanagi-Harada. However, cataract and intraocular pressure elevation developed frequently.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Fluocinolona Acetonida
/
Síndrome Uveomeningoencefálica
/
Glucocorticoides
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Retina
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Níger